The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.